Oss, North Brabant, Netherlands
I am an entrepreneur in Life Sciences and a researcher in behavioral sciences focused on creating high‑performing leadership teams. I design and deliver evidence‑based management and leadership development programmes, and form strategic partnerships that enable organisations to scale, align culture and accelerate performance globally. My approach combines applied behavioral research, diagnostic thinking & behavioral assessment and practical intervention design: bespoke workshops, coaching, and team diagnostics that translate insights into measurable outcomes — clearer accountability, improved decision quality and sustained delivery against strategic targets. Current focus: building leadership systems for R&D and commercial teams in a variety of industries, and conducting applied research on team dynamics and resilient decision‑making. Let’s connect if you’re interested in evidence‑based leadership development, strategic partnerships in Life Sciences, or applied research that boosts team performance. Experiences: Founded and scaled a Life Sciences venture delivering strategic partnerships and leadership development solutions for R&D and commercial teams. Designed and implemented bespoke leadership programmes informed by behavioral science, improving team performance, decision‑making and cross‑functional collaboration. Established and managed international partnerships across Europe, North America and APAC to enable market entry, joint innovation and collaborative growth. Led applied research into team dynamics and leader behaviour; translated findings into practical tools, workshops and coaching curricula for senior leaders.
Cell4Pharma’s is a Dutch Biotechnology company. We deliver to researchers our ciPTEC technology, that is able to accurately identify and eliminate nephro-toxic compounds during preclinical stages of drug development. Our mission is to make life saving drugs faster available to patient & Doctors. ciPTEC technology originates at the beginning of the 21st century. Researchers at the department of Pediatrics at the Radboud University Medical Center in Nijmegen, the Netherlands, were investigating the inherited disorder Nephropathic Cystinosis. Patients manifest before the age of 3 years with a deficient transporter capacity in the renal proximal tubule. To study this disease in the laboratory, Dr. Wilmer et al. cultured proximal tubule cells exfoliated in urine of patients, and, as control, of healthy donors. To establish sufficient study material, the primary tubule cells were immortalized via a technique proven to be successful in other cell types. The group lead by Prof. Dr. Van Den Heuvel and Prof. Dr. Levtchenko succeeded in their endeavors and ciPTEC was born.
As Strategic Advisor to Reelin, I accelerate scalable growth by aligning strategic partnerships, go-to-market motion, and leadership capability. I connect commercial opportunities with internal capability-building so Reelin delivers sustainable value to customers and stakeholders.
Facultas partners is a team based in the US and Europe, with extensive experience working in the life sciences sector on both sides of the Atlantic. facultas is a provider of capital that bridges the Atlantic bringing together early stage life sciences companies to gain scale and lower risks. Based upon our deep knowledge of the life sciences landscape on both sides of the Atlantic we identify companies that exhibit compelling complementarities, and work to bring them together to achieve (1+1=3). We subsequently invest in them via two separate investments funds based in the EU and the US. We build innovative companies from all sectors of life sciences, including drug development, medical devices, digital health technology & services, nutraceuticals and diagnostics with the following attributes.
Dear European Associates, We are formally announcing that Emergenetics International has agreed to acquire the interests in Emergenetics International – Europe. Our previous shareholder and partner, Ron Byron, was a strong leader for the company and in the 4+ years that he ran Emergenetics International efforts in Europe, the company grew in market share and overall reach. More importantly, Ron and his excellent team facilitated lasting partnerships with our core clients and colleagues. We wish Ron all of the best in his new endeavors. Moving forward, Emergenetics International, in partnership with its excellent team of European Country Representatives, will service the European market. You will personally be supported directly from the Denver Office, with immediate effect. Please see attached for a list of key Emergenetics International contacts. Our business will continue to provide high quality products and services, and this internal change will in no way affect our dedication to you. Furthermore, working with all Country Representatives, our combined resources will effectively and efficiently provide high levels of service to the European market. We thank you for your relationship with Emergenetics International, and please feel free to email me with any questions or comments. Sincerely yours, Geil Browning, PhD CEO/Founder Emergenetics International O: 303-660-7920 #2 Inverness Drive East, Ste. 189 Centennial, Colorado 80112 www.Emergenetics.com Revealing Preferences. Realizing Potential.
Strategic Consulting, including Operational Business planning & Marketing strategy development.